Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix CEO Howie McKibbon will be a featured presenter at ASX Small and Mid-Cap Conference on Wednesday, 25 September, and the E&P Small Cap Healthcare Conference on Thursday, 26 September. Botanix will also conduct one-on-one updates with investors.
https://botanixpharma.com/wp-content/uploads/Conference.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-09-24 00:21:482024-09-24 00:22:39Botanix presentation at leading investor conferences and roadshow
Health Editor for The Australian Financial Review, Michael Smith, has featured Botanix Pharmaceuticals in an article titled The five pharma stocks exciting investors.
Smith speaks to leading fund managers about their experiences and professional insights when navigating the biotechnology sector – which they say is back in favour for those willing to sort the ‘winners from the losers’ and ride the wave of success stories like CSL.
Here is an excerpt, quoting Rory Hunter, a portfolio manager for SG Hiscock’s Medical Technology Fund:
‘“It requires a diversified approach to the sector. Once the IP is validated, you are moving into commercialisation and past regulatory approvals.”
‘He likes Botanix for this reason. Its treatment for hyperhidrosis, or severe underarm sweating, affects a large part of the population, and its Japanese partner has already commercialised its treatment. “They will accelerate revenues and profitability. While their IP isn’t quite as exciting, the market they are addressing is significant,” he says.’
https://botanixpharma.com/wp-content/uploads/AFR-.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-09-23 05:43:012024-09-23 05:43:02Botanix Featured in AFR
Video is now available of the Company’s Commercial Day Webinar recorded on 17 September. In the presentation, the Botanix commercial team and their guests provide market insights and a comprehensive update on the launch plans for Sofdra™.
https://botanixpharma.com/wp-content/uploads/Commercial-Day-webinar-1.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-09-18 02:45:282024-09-18 02:50:19Video Available | Commercial Day Webinar
Join the Botanix commercial team and guests for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST for a comprehensive update on commercial launch plans and market insights for Sofdra™.
https://botanixpharma.com/wp-content/uploads/webinar.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-09-11 04:44:262024-09-11 04:44:2617 September Commercial Day Webinar – Registration Open
To view Appendix 4E, click here. Mark your calendar for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST which will provide a comprehensive update on commercial launch plans and market insights for Sofdra™. Registration to follow.
https://botanixpharma.com/wp-content/uploads/Annual-report-1.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-08-30 12:49:002024-08-30 20:06:19Appendix 4E Released and Commercial Day Webinar Announced
Per E&P analyst David Nayagam, Sofdra is poised to provide a new treatment option for primary axillary hyperhidrosis, with “a novel and potentially disruptive model for marketing, reimbursement and distribution.” E&P affirms Speculative Buy and $0.55 Price Targe
Botanix presentation at leading investor conferences and roadshow
/in ASX Releases, Featured, Latest News, News, Presentations /by Haley ChartresBotanix CEO Howie McKibbon will be a featured presenter at ASX Small and Mid-Cap Conference on Wednesday, 25 September, and the E&P Small Cap Healthcare Conference on Thursday, 26 September. Botanix will also conduct one-on-one updates with investors.
Click here to view ASX Release.
Botanix Featured in AFR
/in Featured, Latest News, News /by Haley ChartresHealth Editor for The Australian Financial Review, Michael Smith, has featured Botanix Pharmaceuticals in an article titled The five pharma stocks exciting investors.
Smith speaks to leading fund managers about their experiences and professional insights when navigating the biotechnology sector – which they say is back in favour for those willing to sort the ‘winners from the losers’ and ride the wave of success stories like CSL.
Here is an excerpt, quoting Rory Hunter, a portfolio manager for SG Hiscock’s Medical Technology Fund:
‘“It requires a diversified approach to the sector. Once the IP is validated, you are moving into commercialisation and past regulatory approvals.”
‘He likes Botanix for this reason. Its treatment for hyperhidrosis, or severe underarm sweating, affects a large part of the population, and its Japanese partner has already commercialised its treatment. “They will accelerate revenues and profitability. While their IP isn’t quite as exciting, the market they are addressing is significant,” he says.’
Click here to read the full article.
Video Available | Commercial Day Webinar
/in Featured, Latest News, News, Presentations, Videos /by Haley ChartresVideo is now available of the Company’s Commercial Day Webinar recorded on 17 September. In the presentation, the Botanix commercial team and their guests provide market insights and a comprehensive update on the launch plans for Sofdra™.
17 September Commercial Day Webinar – Registration Open
/in ASX Releases, Featured, Latest News, News /by Haley ChartresJoin the Botanix commercial team and guests for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST for a comprehensive update on commercial launch plans and market insights for Sofdra™.
Pre-register: Click here
Appendix 4E Released and Commercial Day Webinar Announced
/in ASX Releases, Featured, Latest News, News /by Haley ChartresTo view Appendix 4E, click here. Mark your calendar for the Company’s Commercial Day Webinar on
Tuesday 17 September 10:30am AEST / 8:30am AWST which will provide a comprehensive update on
commercial launch plans and market insights for Sofdra™. Registration to follow.
“Potentially Disruptive” | E&P Analysis
/in Featured, Latest News, News /by Haley ChartresPer E&P analyst David Nayagam, Sofdra is poised to provide a new treatment option for primary axillary hyperhidrosis, with “a novel and potentially disruptive model for marketing, reimbursement and distribution.” E&P affirms Speculative Buy and $0.55 Price Targe
View Report.